首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   227084篇
  免费   9774篇
  国内免费   565篇
耳鼻咽喉   2980篇
儿科学   6853篇
妇产科学   5679篇
基础医学   32585篇
口腔科学   7350篇
临床医学   14335篇
内科学   50786篇
皮肤病学   6929篇
神经病学   18526篇
特种医学   5764篇
外国民族医学   30篇
外科学   27191篇
综合类   1127篇
一般理论   39篇
预防医学   24580篇
眼科学   5323篇
药学   16915篇
中国医学   859篇
肿瘤学   9572篇
  2023年   1174篇
  2022年   1708篇
  2021年   4297篇
  2020年   2392篇
  2019年   4375篇
  2018年   6355篇
  2017年   4049篇
  2016年   4178篇
  2015年   4564篇
  2014年   5769篇
  2013年   8480篇
  2012年   13452篇
  2011年   14025篇
  2010年   7423篇
  2009年   6135篇
  2008年   11587篇
  2007年   12236篇
  2006年   11850篇
  2005年   11549篇
  2004年   10656篇
  2003年   9945篇
  2002年   9571篇
  2001年   6848篇
  2000年   7393篇
  1999年   5936篇
  1998年   1491篇
  1997年   1065篇
  1992年   3121篇
  1991年   2925篇
  1990年   2866篇
  1989年   2483篇
  1988年   2317篇
  1987年   2157篇
  1986年   2169篇
  1985年   2018篇
  1984年   1487篇
  1983年   1289篇
  1979年   1609篇
  1978年   1093篇
  1977年   1022篇
  1975年   1162篇
  1974年   1440篇
  1973年   1469篇
  1972年   1389篇
  1971年   1336篇
  1970年   1278篇
  1969年   1335篇
  1968年   1317篇
  1967年   1188篇
  1966年   1081篇
排序方式: 共有10000条查询结果,搜索用时 12 毫秒
991.
992.
The one disease associated with the greatest morbidity and mortality in industrialized countries is coronary heart disease (CHD). High density lipoprotein (HDL) is one of the most important independent protective factors for the arteriosclerosis which underlies CHD. Paraoxonase 1 (PON1) is an enzyme that confers antioxidant properties to HDL. In vitro, PON1 hydrolyzes a large variety of endogenous or exogenous substrates, some of which are clearly involved in the progression of arteriosclerosis. A close relationship between PON1 deficiency and accelerated progression of arteriosclerosis has been found in animal models. Moreover, PON1 activity is reduced in high oxidative stress diseases such as CHD, dyslipoproteinemias, inflammatory processes, diabetes and certain neuropathies. Reduced PON1 enzyme activity is associated with several arteriosclerosis-related diseases. The most thoroughly studied genetic variant of PON1 is PON1-192, in which the R allele is associated with elevated paraoxonase activity. This allele, present in 24.8% of the Italian population, is found in up to 78.9% of the population of Ecuadorian Cayapa Indians. A metaanalysis of studies on the relationship between CHD and the R allele showed the latter to be an independent risk factor for this disease, with an odds ratio of 1.18 (95% confidence interval, 1.10-1.27). The PON1 enzyme is a potentially useful new qualitative indicator in addition to the well known reverse cholesterol transport capacity associated with high plasma levels of HDL.  相似文献   
993.
994.

Background

The most common cystic fibrosis (CF)-causing mutation is deltaF508 (F508del), which is present in 28% of CF Spanish patients. While the literature based on real-life studies on CF patients homozygous F508del treated with lumacaftor/ivacaftor is limited, it demonstrates the need for better strategies to prevent related adverse events (AEs) as well as the development of newer drugs.

Methods

We conducted a multicenter, retrospective, observational study to describe the effects of lumacaftor/ivacaftor treatment in real-life in Spain. 20 CF patients were included, all aged 6 and upwards and presented with ppFEV1 < 40%, chosen from CF units country-wide. For the purposes of the study, they were treated with lumacaftor/ivacaftor 200/125 mg two tablets twice a day on a compassionate use programme throughout 2016. The primary endpoint was measured in all of the sample patients. Data were analysed from ppFEV1 at baseline and was measured every 6 months.

Results

The mean age was 26.65 (range of 10–45), while the mean ppFEV1 before the treatment was 32.4% and mean BMI was 19.9 kg/m2. We analysed the changes in ppFEV1 and BMI from baseline during the treatment with lumacaftor/ivacaftor, but no differences were found. However, a moderate association between days of intravenous antibiotic needed and the use of lumacaftor/ivacaftor (p = 0.001) was established. Indeed, under the lumacaftor/ivacaftor, patients required 5.8 days of intravenous antibiotic treatment compared to 14.9 days prior to study. Also, severe pulmonary exacerbations requiring hospitalisation were statistically fewer under lumacaftor/ivacaftor treatment (p = 0.003). Finally, 75% of the sample presented with AEs, which led 35% of the subjects to discontinue the treatment.

Conclusions

While treatment with lumacaftor/ivacaftor resulted in an improvement in the number of pulmonary severe exacerbations, no improvement in ppFEV1 or BMI was found.  相似文献   
995.
Background: the aim of the present study is to investigate the responsible mechanism of different adverse reactions suffered by five patients, aged between six and thirty years-old, after consumption of barnacle. The symptoms were angioedema, dyspnea, generalized urticaria, conjunctivitis and one of them suffered from anaphylactic reaction. Four patients had personal atopic history.Methods: the allergic study included prick by prick test with raw and boiled barnacle and prick-test with a standardized battery of shellfish and neumoallergens, specific-IgE determination to barnacle, crustacean and house-dust-mite and SDS-PAGE immunoblotting to barnacle. Even though an oral challenge was proposed to three of the patients, they were reluctant to do the test and eventually the challenges were not carried out.Results: prick to prick tests were positive to barnacle for all of them. Specific-IgE was found in four patients. The western blotting results showed an IgE-binding band whose apparent molecular mass ranged between 58 and 68 kDa.Conclusions: barnacle could induce IgE-mediated adverse reaction. Our study has demonstrated the presence of an IgE-binding protein in barnacle extracts ranged between 58 and 68 kDa of molecular mass. It has not been previously described a crustacean allergen with the same molecular mass, so it could be a specific allergen from barnacle. We believe that further study will confirm this is the case.  相似文献   
996.
A total of 83 bypasses were studied. Angiographic results demonstrated occlusion in 3 of 24 bypass of internal mammary artery placed in the anterior descending artery, 2 in the right coronary artery, 1 in the posterolateral of the circumflex and 1 in the first diagonal branch, with a total occlusion average of 8.4% within the first 8 days. We found a good correlation between the coronarographic angiograms and the positivity or negativity of the echo-electrocardiographic tests, during atrial pacing. We believe that this simple method could be done routinely in all the patients after coronary surgery, to decide the need of a new coronary angiogram. Furthermore, this study shows that the occlusion of a single coronary bypass does not produce myocardial infarction, detectable by enzymatic measures or by resting EKG. This method also detects the early post-operatory sinus sick syndrome.  相似文献   
997.
Direct myocardial revascularization techniques has earned great acceptance in the treatment of ischemic coronary syndromes in the past two decades. Almost since its beginnings the procedure was done with the aid of extracorporeal circulation, since the technical accessibility with cardiac standstill further helped to evolve the procedure. As years went by, complications due to the use of the pump became evident, such as microembolism, bleeding disorders, and others. Besides this, there is a special group of patients, those with high surgical risk, with preexisting pulmonary, hepatic or cerebral disease, who benefit a great deal when bypass grafting procedure is done without the pump. In this article we delineate the indications, contraindications, and the procedure itself based in our personal experience, reporting our first five patients with this technique.  相似文献   
998.
Breast Cancer Research and Treatment - Evidence on non-steroidal anti-inflammatory drugs (NSAID) use and breast cancer risk shows a slightly protective effect of these drugs, but previous studies...  相似文献   
999.
1000.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号